uniQure N.V.

Listed Company

QURECIK 0001590560NasdaqLarge AcceleratedPharmaceutical PreparationsNLFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-198.97M

Total Assets

$824.91M

Equity

$198.90M

Shares Out

62.53M

Op. Cash Flow

$-177.96M

Business

uniQure N.V. is a leader in gene therapy developing one‑time administered genomic medicines to treat rare and other serious diseases. It advances a focused pipeline of AAV‑based gene therapy product candidates including AMT‑130 for Huntington’s disease, AMT‑162 for SOD1‑ALS, AMT‑260 for refractory mesial temporal lobe epilepsy, AMT‑191 for Fabry disease, and the commercial product HEMGENIX® through a collaboration. Its activities encompass research and development, clinical trials, next‑generation capsid and cargo technology development, intellectual property management, and manufacturing partnerships. It conducts clinical programs and commercial supply through collaborations and partner distribution across the U.S., Europe and other jurisdictions.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	16	27	16	106	524
Cost of license revenues	−2	−1	−65,000	−1	−25
Cost of contract manufacturing revenues	—	−17	−14	−2	—
Research and development expenses	−141	−144	−215	−198	−144
Selling, general and administrative expenses	−65	−53	−75	−55	−56
Total operating expenses	−208	−215	−303	−256	−225
Other income	14	8	6	7	12
Other expense	−8	−5	−2	−800,000	−876,000
Loss from operations	−185	−184	−283	−143	311
Interest income	17	21	20	609,000	162,000
Interest expense	−62	−64	−42	−12	—
Foreign currency gains / (losses), net	26	−11	−2	23	30
Other non-operating gains, net	11	—	—	3	−160,000
Loss before income tax expense	−193	−237	−307	−128	333
Income tax expense	−6	−2	−2	1	−3
Net loss	−199	−240	−308	—	—
Foreign currency translation (losses) / gains, net	−6	426,000	7	−29	−39
Defined benefit pension gain / (loss), net of taxes	771,000	327,000	−2	—	—
Total comprehensive loss	−204	−239	−304	−156	291
Basic net loss per ordinary share	−3.46	−4.92	−6.47	−2.71	7.17
Diluted net loss per ordinary share	−3.46	−4.92	−6.47	−2.71	7.04
Weighted average shares - basic	58	49	48	47	46
Weighted average shares - diluted	58	49	48	47	47

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	80	159	241	228	556
Current investment securities	542	209	377	125	—
Accounts receivable	6	6	4	102	59
Prepaid expenses	21	9	15	12	11
Other current assets and receivables	7	8	3	3	3
Total current assets	656	390	652	477	628
Property, plant and equipment, net	14	20	47	51	44
Other investments	30	27	—	—	—
Operating lease right-of-use assets	13	14	29	33	26
Intangible assets, net	73	71	60	—	—
Goodwill	25	22	26	26	28
Deferred tax assets, net	9	10	12	15	16
Other non-current assets	6	1	3	6	6
Total non-current assets	169	166	180	228	181
Total assets	825	557	832	705	809
Accounts payable	5	7	7	11	3
Accrued expenses and other current liabilities	41	29	31	31	28
Liability related to pre-funded warrants	13	—	—	—	—
Current portion of operating lease liabilities	4	4	8	8	6
Total current liabilities	63	40	74	76	37
Long-term debt	50	51	102	103	101
Liability from royalty financing agreement	473	435	394	—	—
Operating lease liabilities, net of current portion	10	11	28	32	29
Contingent consideration	19	11	15	9	30
Deferred tax liability, net	8	7	8	8	13
Other non-current liabilities, net of current portion	4	8	4	935,000	4
Total non-current liabilities	563	523	550	153	177
Total liabilities	626	563	624	229	213
Commitments and contingencies	—	—	—	—	—
Ordinary shares, 0.05 par value: 80,000,000 shares authorized as of December 31, 2025 and December 31, 2024 and 62,336,717 and 48,988,087 ordinary shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	4	3	3	3	3
Additional paid-in-capital	1,582	1,173	1,149	1,113	1,077
Accumulated other comprehensive loss	−58	−53	−54	−58	−29
Accumulated deficit	−1,329	−1,130	−890	−582	−455
Total shareholders' equity / (deficit)	199	−7	208	476	596
Total liabilities and shareholders' equity / (deficit)	825	557	832	705	809

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−199	−240	−308	−127	330
Depreciation and amortization	15	13	12	9	7
Amortization of discount on investment securities	−10	−11	−11	—	—
Share-based compensation expense	18	22	35	34	26
Royalty financing agreement interest expense, net of interest paid	39	44	26	—	—
Deferred tax expense	2	2	2	−1	3
Changes in fair value of contingent consideration	6	−2	16	—	—
Changes in fair value of liability related to pre-funded warrants	−12	—	—	—	—
Unrealized foreign exchange (gains) / losses, net	−23	15	−2	−22	−31
Other items, net	−5	−4	5	2	−3
Accounts receivable, prepaid expenses, and other current assets and receivables	−9	−2	−1	—	—
Accounts payable	−3	2	−4	9	−727,000
Accrued expenses, other liabilities, and operating leases	4	−6	−5	3	9
Contingent consideration milestone payments	—	−20	−2	—	—
Inventories	—	2	−7	−7	—
Contract asset related to CSL Behring milestone payments	—	—	100	−45	−55
Net cash used in operating activities	−178	−183	−146	−145	288
Proceeds on maturity of debt securities	337	534	168	—	—
Investment in debt securities	−658	−360	−366	−163	0
Divestment of commercial manufacturing facility	—	−8	—	—	—
Purchases of property, plant, and equipment	−439,000	−3	−7	−18	−17
Net cash (used in) / generated from investing activities	−322	163	−206	−183	−67
Proceeds from follow-on public offerings of ordinary shares, net of issuance costs	381	—	—	—	—
Proceeds from issuance of pre-funded warrants, net of issuance costs	23	—	—	—	—
Proceeds from issuance of ordinary shares related to employee stock options and purchase plans	11	2	308,000	1	3
Repayment of long-term debt	—	−53	—	—	—
Contingent consideration milestone payments	—	−9	−8	—	—
Proceeds from royalty financing agreement, net of issuance costs	—	—	370	—	—
Net cash generated from / (used in) financing activities	415	−59	363	1	95
Currency effect on cash, cash equivalents and restricted cash	6	−5	2	−2	−4
Net (decrease) / increase in cash, cash equivalents and restricted cash	−79	−84	13	−328	312
Cash paid for interest	−25	−21	−17	−9	−7
Non-cash decrease in accounts payables and accrued expenses and other current liabilities related to purchases of property, plant, and equipment	−99,000	−672,000	−513,000	−964,000	1

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro